查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美阿片类药物市场规模、份额、趋势分析报告：按按产品、用途、地区和细分市场预测，2023-2030 年
市场调查报告书
商品编码
1362903

北美阿片类药物市场规模、份额、趋势分析报告：按按产品、用途、地区和细分市场预测，2023-2030 年

North America Opioids Market Size, Share & Trends Analysis Report By Product (IR/Short-acting, ER/Long-acting), By Application (Pain Relief, Anesthesia,Cough Suppression), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

北美阿片类药物市场成长与趋势

Grand View Research, Inc. 的一项新研究显示，从 2023 年到 2030 年，北美阿片类药物市场预计将以 0.8% 的复合年复合成长率增长，到 2030 年达到 153 亿美元。

有利的法规和医疗改革将为开发新的防滥用鸦片类药物的研发和商业化工作提供有利的环境，从而在预测期内促进产业成长。此外，大公司正在投入大量资金开发防滥用技术，旨在使药物不易被窜改。其他活动包括使用物理或化学屏障来阻止阿片类药物的方便提取，在製剂中添加驱避剂以在提取时产生不良影响，以及依靠酶活性将其转化为活性形式。例子包括阿片类药物的製剂前药。这些

这种防篡改鸦片类製剂有望减少误用的发生率。

阿片类药物是慢性疼痛管理的支柱，用于缓解各种疼痛状况。阿片类药物，包括可待因和吗啡，常用作止咳药。可待因被认为是止咳药的黄金标准，因为它几乎没有副作用。此外，由于这些麻醉剂作用于胃肠道受体，因此它们也用于治疗大肠激躁症引起的腹泻。此外，週边作用的洛哌丁胺常用于控制腹泻。因此，阿片类药物市场的有益成长在于其在治疗咳嗽、腹泻和疼痛等多种病症方面的用途。

北美阿片类药物市场报告亮点

  • 到 2022 年，缓释性阿片类药物市场将占最大份额，超过 53.8%。该领域的主导地位是由于这些药物在慢性疼痛治疗​​中的高利用率以及创新剂型（例如经皮吸收贴片）的开发。
  • 由于频繁的产品召回以及与其使用相关的严重副作用，含有吗啡和可待因的速释剂型的市场占有率预计将下降。
  • 按用途来看，止痛领域占2022年销售额的最大份额。化疗和放射线治疗期间引起的大量疼痛是癌症领域越来越多地采用这些药物的一个主要要素。
  • 术后疼痛管理领域预计将成为疼痛缓解类别中成长最快的用途。由于其在术后疼痛管理中的高度适用性，预计外科手术数量的增加将在不久的将来推动阿片类药物渗透到领域。
  • 2022年，美国以95.6%的销售份额占据市场主导地位。主要要素之一是老年人口的增加，在临床上更罹患类风湿性关节炎等末期疾病，正在对该市场产生积极影响。
  • 此外，越来越多地使用鸦片类药物来治疗创伤和损伤、严重慢性残疾疾病和手术后的疼痛，也推动了北美地区的市场成长。
  • 由于癌症疼痛、肌肉骨骼疾病和术后疼痛等各种疼痛相关疾病的患病不断增加而产生的需求，预计加拿大在预测期内将以 1.2% 的最快速度增长。此外，加拿大高龄化，进一步增加了对鸦片类药物的需求。

目录

第1章调查方法与范围

第2章执行摘要

第3章北美鸦片类药物市场变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 北美阿片类药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章北美鸦片类药物：产品估算与趋势分析

  • 北美阿片类药物市场：要点
  • 北美阿片类药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 速效/短效鸦片类药物
    • 2018年至2030年速效/短效阿片类药物市场估计与预测
    • 可待因
    • 羟考酮
    • 氢可酮
    • 芬太尼
    • 吗啡
    • 羟基吗啡酮
    • 羟吗啡酮
    • 丙氧芬
    • 其他的
  • 缓释性/长效型鸦片类药物
    • 2018 年至 2030 年缓释性/长效阿片类药物市场估计与预测
    • 羟考酮
    • 氢可酮
    • 美沙酮
    • 芬太尼
    • 吗啡
    • 羟吗啡酮
    • 他喷他多
    • 丁丙诺啡
    • 氢吗啡酮
    • 其他的

第5章北美鸦片类药物市场：用途估算与趋势分析

  • 北美阿片类药物市场：要点
  • 北美阿片类药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 止痛药
  • 麻醉
  • 止咳药
  • 止泻
  • 戒成瘾

第6章北美鸦片类药物市场：区域估计与趋势分析

  • 区域展望
  • 北美阿片类药物市场（按地区）：主要市场要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Purdue Pharma LP
    • Janssen Global Services, LLC
    • Hikma Pharmaceuticals PLC
    • Pfizer Inc.
    • AbbVie Inc.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd.
    • Mallinckrodt Pharmaceuticals
    • Endo Pharmaceuticals
    • Teva Pharmaceutical Industries
Product Code: GVR-1-68038-075-0

North America Opioids Market Growth & Trends:

The North America opioids market is expected to reach USD 15.3 billion by 2030, growing at an estimated CAGR of 0.8% from 2023 to 2030, according to a new study by Grand View Research, Inc.. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.

Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcoticsare used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, theprofitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.

North America Opioids Market Report Highlights:

  • The extended-release opioids segment accounted for the largest share over 53.8% in 2022. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.
  • Market share of the immediate-release dosage forms including morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use.
  • In terms of applications, The pain relief segment dominated the market with the largest revenue share in 2022. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.
  • The post-operative pain management segment is expected to be the fastest growing application in the pain relief category. As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sector penetration of opioids in the near future.
  • The U.S. dominated the market with the highest revenue share of 95.6% in 2022. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.
  • In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region
  • The Canada is expected to grow at the fastest growth rate of 1.2% over the forecast period owing to the demand arising from the increasing prevalence of various pain-related conditions, such as cancer-related pain, musculoskeletal disorders, and post-operative pain. In addition, the growing aging population in Canada has further contributed to the demand for opioids.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. North America Opioids Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. North America Opioids Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. North America Opioids: Product Estimates & Trend Analysis

  • 4.1. North America Opioids Market: Key Takeaways
  • 4.2. North America Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Immediate Release/ Short-acting Opioids
    • 4.3.1. Immediate release/ Short acting opioids market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Codeine
      • 4.3.2.1. Codeine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Oxycodone
      • 4.3.3.1. Oxycodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4. Hydrocodone
      • 4.3.4.1. Hydrocodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5. Fentanyl
      • 4.3.5.1. Fentanyl market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.6. Morphine
      • 4.3.6.1. Morphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.7. Hydroxymorphone
      • 4.3.7.1. Hydroxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.8. Oxymorphone
      • 4.3.8.1. Oxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.9. Propoxyphene
      • 4.3.9.1. Propoxyphene market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.10. Others
      • 4.3.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Extended Release/Long-acting Opioids
    • 4.4.1. Extended release/Long-acting opioids market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Oxycodone
      • 4.4.2.1. Oxycodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Hydrocodone
      • 4.4.3.1. Hydrocodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Methadone
      • 4.4.4.1. Methadone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Fentanyl
      • 4.4.5.1. Fentanyl market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Morphine
      • 4.4.6.1. Morphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Oxymorphone
      • 4.4.7.1. Oxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.8. Tapentadol
      • 4.4.8.1. Tapentadol market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.9. Buprenorphine
      • 4.4.9.1. Buprenorphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.10. Hydromorphone
      • 4.4.10.1. Hydromorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.11. Others
      • 4.4.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. North America Opioids Market: Application Estimates & Trend Analysis

  • 5.1. North America Opioids Market: Key Takeaways
  • 5.2. North America Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Pain Relief
    • 5.3.1. Pain relief market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.2. Cancer Pain
      • 5.3.2.1. Cancer pain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.3. Post-Operative Care
      • 5.3.3.1. Post-operative care market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.4. Lower Back Pain
      • 5.3.4.1. Lower back pain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.5. Orthopedic
      • 5.3.5.1. Orthopedic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.6. Neuropathic
      • 5.3.6.1. Neuropathic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.7. Fibromyalgia
      • 5.3.7.1. Fibromyalgia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Anesthesia
    • 5.4.1. Anesthesia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Cough Suppression
    • 5.5.1. Cough suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Diarrhea Suppression
    • 5.6.1. Diarrhea suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. De-addiction
    • 5.7.1. De-addiction market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. North America Opioids Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. North America Opioids Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Purdue Pharma L.P.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Janssen Global Services, LLC
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Hikma Pharmaceuticals PLC
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Pfizer Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. AbbVie Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Sanofi
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Sun Pharmaceutical Industries Ltd.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Mallinckrodt Pharmaceuticals
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Endo Pharmaceuticals
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Teva Pharmaceutical Industries
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America opioids market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America opioids market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America opioids market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. opioids market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. opioids market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada opioids market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada opioids market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Opioids: Market outlook
  • Fig. 9 Opioids: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 North America opioids market driver impact
  • Fig. 14 North America opioids market restraint impact
  • Fig. 15 North America opioids market strategic initiatives analysis
  • Fig. 16 North America opioids market: Product movement analysis
  • Fig. 17 North America opioids market: Product outlook and key takeaways
  • Fig. 18 Immediate release/ Short acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 19 Codeine market estimates and forecasts, 2018 - 2030
  • Fig. 20 Oxycodone market estimates and forecasts, 2018 - 2030
  • Fig. 21 Hydrocodone market estimates and forecasts, 2018 - 2030
  • Fig. 22 Fentanyl market estimates and forecasts, 2018 - 2030
  • Fig. 23 Morphine market estimates and forecasts, 2018 - 2030
  • Fig. 24 Hydroxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 25 Oxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 26 Propoxyphene market estimates and forecasts, 2018 - 2030
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030
  • Fig. 28 North America opioids market: Application movement analysis
  • Fig. 29 North America opioids market: Application outlook and key takeaways
  • Fig. 30 Extended release/Long acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 31 Oxycodone market estimates and forecasts, 2018 - 2030
  • Fig. 32 Hydrocodone market estimates and forecasts, 2018 - 2030
  • Fig. 33 Methadone market estimates and forecasts, 2018 - 2030
  • Fig. 34 Fentanyl market estimates and forecasts, 2018 - 2030
  • Fig. 35 Morphine market estimates and forecasts, 2018 - 2030
  • Fig. 36 Oxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 37 Tapentadol market estimates and forecasts, 2018 - 2030
  • Fig. 38 Buprenorphine market estimates and forecasts, 2018 - 2030
  • Fig. 39 Hydromorphone market estimates and forecasts, 2018 - 2030
  • Fig. 40 Others market estimates and forecasts, 2018 - 2030
  • Fig. 41 North America opioids market: Regional movement analysis
  • Fig. 42 North America opioids market: Regional outlook and key takeaways
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030